Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer

Recruiting now · Not applicable

Conditions studied: Ovarian Cancer

In brief

A prospective cohort imaging study in a single institution to evaluate 68Ga- FAPI-46 and 18F-FDG PET/CT imaging for detecting recurrent tumor lesions in patients of ovarian cancer with CA125 elevation from complete response after therapy

Key facts

Study ID

NCT06232122

Run by

Chang Gung Memorial Hospital

People needed

45

Starts

2022-08-01

Expected to finish

2028-07-31

Last updated by the study team

2024-01-30

Who can join

Age: 30 and older, up to 80. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically proven ovarian cancer with complete response after therapy
• Age between 30 and 80
• Elevation of serum CA125 value above the normal range (>35 U/mL) or doubling of serum CA125 value within the normal range
• ECOG performance status grade 0 or 1 and willing to receive further therapy if disease recurrence is confirmed
• Willing to enter this prospective study with signed informed consent form

You may not qualify if…

• Patients with history of other malignancy
• Patients who are pregnant or lactating
• Patients with fasting fingerstick glucose level higher than 200 mg/dl
• Known allergic reactions to components of the radiopharmaceutical solutions for intravenous injection for 68Ga-FAPI-46 or 18F-FDG imaging studies
• Patients who are incapable of lying still for 30 minutes to receive the PET/CT scan as assessed by investigators

Where it is running

• Chang-Gung Memorial Hospital, Linkou Branch — Taoyuan City, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.